非酒精性脂肪性肝病患者血清和肝组织胰腺衍生因子水平变化及意义

doi:10.3969/j.issn.1672-5069.2014.05.009

摘要/Abstract

摘要： 目的研究胰腺衍生因子（PANDER）在非酒精性脂肪性肝病（NAFLD）患者血清和肝组织的水平。方法纳入经肝组织病理学活检证实的NAFLD患者41例,以及20例正常人（NC）,根据NAFLD活动性积分（NAS）, 将NAFLD患者分为单纯性脂肪肝（NAFL）10例和非酒精性脂肪性肝炎（NASH）31例。采用ELISA法检测受试者血清和肝组织PANDER水平;采用实时荧光定量PCR法检测肝组织PANDER mRNA水平的变化。另外,收集所有研究对象的人体测量学、生化及代谢指标,分别比较PANDER水平及与其相关性。结果NAFLD患者血清PANDER水平为（3.38±1.99） ng/ml,较NC组[（0.94±0.60） ng/ml]升高,差异有统计学意义（P<0.05）;NAFLD患者肝组织PANDER水平为（3.27±2.49） ng/ml,显著高于NC组[（0.98±0.73） ng/ml,P<0.05];NAFL组和NASH组血清PANDER水平分别为（3.42±2.39） ng/ml和（3.36±1.91） ng/ml,肝组织PANDER水平分别为（2.33±1.52） ng/ml和（3.58±2.68） ng/ml,差异无统计学意义;血清PANDER与肝组织PANDER水平、BMI、腰围、臀围、TG、FBG、FINS、HMOA-IR的相关系数分别0.425、0.643、0.637、0.375、0.411、0.487、0.512和0.547,均呈正相关关系（P<0.05）,与IAI（r=-0.544）、HDL-C（r=-0.396）呈负相关（P<0.05）;肝组织PANDER水平与血清PANDER水平、BMI和腰围的相关系数分别为0.425、0.379和0.427,也呈正相关（P<0.05）。结论PANDER可能通过影响胰岛素抵抗和糖脂代谢参与NAFLD的发生与发展。

关键词: 非酒精性脂肪性肝病, 胰腺衍生因子, 胰岛素抵抗, 脂质, 糖代谢

Abstract: Objective To explore the serum and hepatic level of pancreatic derived factor （PANDER） in patients with non-alcoholic fatty liver diseases （NAFLD）. Methods Forty-one patients with NAFLD confirmed by liver biopsy and 20 healthy persons were included in this study and the patients with NAFLD were further divided into NAFL group （n=10） and NASH group （n=31 cases） according to the NAFLD activity score （NAS）. Serum and hepatic level of PANDER were detected by ELISA method and hepatic level of PANDER mRNA was determined by real-time PCR. Anthropometry data,biochemical and metabolic parameters of all subjects were collected and compared between different groups. Results The serum level and hepatic level of PANDER in patients with NAFLD were（3.38±1.99） ng/ml and（3.27±2.49） ng/ml,respectively,significantly higher than those in healthy controls[（0.94±0.60） ng/ml,（0.98±0.73） ng/ml）,respectively,P<0.05];No significant difference in serum level [（3.42±2.39） ng/ml vs. （3.36±1.91） ng/ml] and hepatic level [（2.33±1.52） ng/ml vs. （3.58±2.68） ng/ml] of PANDER between patients with NAFL and NASH;Serum level of PANDER were positively correlated with hepatic level of PANDER （r=0.425）,BMI（r=0.643）,waist circumference（r=0.637）,hip circumference（r=0.375,triglyceride （r=0.411）,fasting blood glucose（r=0.487）,fasting insulin（r=0.512） and homeostasis model assessment index （HOMA-IR,r=0.547,P<0.05）,and negatively correlated with insulin action index（r=-0.544） and high-density lipoprotein cholesterol（r=-0.396,P<0.05）. Hepatic level of PANDER were positively correlated with serum PANDER level（r=0.425）,body mass index（r=0.379） and waist circumference（r=0.427,P<0.05）. Conclusion PANDER plays an important role in the pathogenesis of NAFLD by affecting body insulin resistance and glucose and lipid metabolisms.

Key words: Nonalcoholic fatty liver diseases, Pancreatic derived factor, Insulin resistance, Lipid, Glucose metabolism

杨帆, 李良平. 非酒精性脂肪性肝病患者血清和肝组织胰腺衍生因子水平变化及意义[J]. 实用肝脏病杂志, 2014, 17(5): 479-483.

Yang Fan, Li Liangping. Serum and hepatic level of pancreatic derived factor in patients with non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(5): 479-483.

参考文献

[1] Li J,Chi Y,Wang C,et al. Pancreatic-derived facter promotes lipogenesis in the mouse liver:role of the Forkhed box 1 signaling pathway.Hepatology,2011,53（6）:1906-1916.
[2] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南.胃肠病学,2010,15（11）：676-680.
[3] Kleiner DE,Brunt EM,Van Natta M,et a1. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology,2005,41（6）:1313-1321.
[4] Xu W,Gao Z,Wu J,et al.Interferon-gamma-induced regulation of the pancreatic derived cytokine FAM3B in islets and insulin secreting beta TC3 cells. Mol Cell Endocrinol,2005,240（l-2）:74-81.
[5] Zhu Y,Xu G,Patel A,et al. Cloning,expression,and initial characterization of a novel cytokine-like gene family. Genomics, 2002,80（2）:144-150.
[6] Burkhardt BR,Yang MC,Robert CE,et al. Tissue-specific and glucose-responsive expression of the pancreatic derived factor（ PANDER） promoter. Biochim Biophys Acta,2005,1730（3）:215-225.
[7] Cao X,Gao Z,Robert CE,et al. Pancreatic-derived factor （FAM3B）,a novel islet cytokine,induces apoptosis of insulin-secreting beta-cell. Diabetes,2003,52（9）:2296-2303.
[8] Cao X,Yang J,Burkhardt BR,et al. Effects of overexpression of pancreatic derived factor （FAM3B） in isolated mouse islets and insulin-secreting beta TC3 cells. Am J Physiol Endocrinol Metab,2005,289（4）:E543-E550.
[9] Yang J,Wang C,Burkhardt BR,et al. PANDER binds to the liver cell membrance and inhibits insulin signaling in HepG2 cells. FEBS Letters,2009,583（18）:3009-3015.
[10] Burkhardt BR,Greene SR,Whire P,et al.PANDER-induced cell-death genetic networks in islets reveal central role for caspase-3 and cyclin-dependent kinase inhibitor 1A（p21） .Gene,2006,369（3）:134-141.
[11] Yang J,Robert CE,Burkhardt BR,et al. Mechanisms of glucose-induced secretion of pancreatic-derived factor（PANDER or FAM3B） in pancreatic beta-cells. Diabetes,2005,54（11）:3217-3228.
[12] Sachdev MS,Riely CA,Madan AK. Nonalcoholic fatty liver disease of obesity. Obesity Surg,2006,16（11）:1412-1419.
[13] Wang O,Cai K,Pang S,et al. Mechanisms of glucose-induced expression of pancreatic derived factor in pancreatic beta-cells .Endocrinology,2008,149 （2）:672-680.
[14] Aller R,De Luis DA,Izaola O,et al. Lysasn polymorphism of leptin receptor,leptin levels and insulin resistance in patients with non alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci,2012,16（3）:335-341.
[15] Valenti L,Rametta R,Dongiovanni P,et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes,2008,57（5）:1355-1362.
[16] Gross DN,Wan M,Birnbaum MJ. The role of FOXO in the regulation of metabolism .Curr Diab Rep,2009,9（3）:208-214.
[17] Dong XC,Copps KD,Guo S,et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation.Cell Metab,2008,8（1）:65-76.